Is Density Spectral Array Display Along With Bispectral Index Superior to the Display of Bispectral Index Alone

NCT ID: NCT07232160

Last Updated: 2025-11-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

70 participants

Study Classification

OBSERVATIONAL

Study Start Date

2026-06-30

Study Completion Date

2029-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A study to evaluate the use of density spectral array display in comparison with Bispectral index in a clinical setting.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Propofol-based total intravenous anesthesia (TIVA) is a popular general anesthesia (GA) technique with an increased risk of unintended awareness under GA, which can be a devastating and life-changing complication. Age-related changes may impact the performance of EEG-derived depth of anesthesia indices in those older than 65 years, particularly in the presence of cognitive disorders.

Hypothesis: In comparison to monitor 1 (BIS only), monitor 2 (DSA + BIS) will have higher sensitivity and specificity to detect recovery

Objectives:

Investigators will prospectively measure the sensitivity and specificity of monitor 1 versus monitor 2 in patients older than 65 years receiving propofol-based TIVA.

Methods:

Investigators will recruit 70 participants from the Royal Brisbane and Women's Hospital (RBWH) who are aged 65 years or older and scheduled for elective endovascular or endoscopic urologic procedures.

Investigators aim to determine whether the display of DSA can enhance the sensitivity and specificity of depth of anesthesia monitors in detecting sudden changes in anesthetic depth in older patients. This may enhance the detection of inadequate administration or delivery of propofol and may lower the incidence of unintended awareness under general anesthesia in that age group.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Awareness During General Anesthesia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Primary cohort

* Age ≥ 65 years undergoing elective procedures of 1-3 hours' duration requiring GA.
* Procedures in which a DoA monitor can be applied to the forehead.
* Patients receiving intravenous propofol and opiate anesthesia using supraglottic airway device.
* Patient able to provide informed consent.

Depth of anesthesia monitoring using processed EEG

Intervention Type DEVICE

Comparison of processed EEG monitor (Bispectral index) with and without Density spectral array

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Depth of anesthesia monitoring using processed EEG

Comparison of processed EEG monitor (Bispectral index) with and without Density spectral array

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 65 years undergoing elective procedures of 1-3 hours' duration requiring GA.
* Procedures in which a DoA monitor can be applied to the forehead.
* Patients receiving intravenous propofol and opiate anaesthesia using supraglottic airway device.
* Patient able to provide informed consent.

Exclusion Criteria

* Administration of ketamine/dexmedetomidine.
* Administration of inhaled anaesthetic agents or nitrous oxide
* Administration of muscle relaxation
Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medtronic

INDUSTRY

Sponsor Role collaborator

The University of Queensland

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Michael Boules, MB BCh

Role: PRINCIPAL_INVESTIGATOR

The University of Queensland

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Royal Brisbane and Women's Hospital

Herston, Queensland, Australia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Australia

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Michael Boules, MB BCh, FANZCA

Role: CONTACT

+61450506350

Victoria Eley, PhD

Role: CONTACT

+6136468111

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Christine Woods

Role: primary

+6136468111

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2025/HE000173

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The DistaSense VITALS Study
NCT07217327 RECRUITING
SMART TRENDS Study
NCT05957406 COMPLETED NA